Actinogen Medical (ASX: ACW)

Last close As at 17/01/2025

AUD0.03

0.00 (0.00%)

Market capitalisation

AUD82m

Actinogen Medical is an ASX-listed Australian biotech developing its lead asset Xanamem, a specific and selective 11beta-HSD1 inhibitor designed to treat cognitive impairment (CI), which occurs in chronic neurodegenerative and neuropsychiatric diseases.

Latest Insights

View More
Actinogen Medical

Sector

Healthcare

Equity Analyst

Pooya Hemami, OD MBA, CFA

Analyst - Healthcare

Jyoti Prakash

Jyoti Prakash, CFA

Analyst, Healthcare

Key Management

  • Dr Steven Gourlay

    CEO and MD

  • Michael Roberts

    Head of investor relations

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free